RxDoctor Payments Data

Ian Furtado, MD

Family Medicine · Alma, GANPI 1912358755

Payments from drug & device makers

$2,028in general payments, 2019–2025

Across 42 payments — averaging $48.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$414
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$350
  • Lilly USA, LLC$230
  • Amgen$126
  • Novo Nordisk$125
  • Bayer$125
  • plus $660 from 11 others

What the payments were for

  • Food & beverage$2,028100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,028 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$19,505
Medicare patients
81
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide128$134,737
EliquisApixaban108$72,267
OzempicSemaglutide57$57,771
VraylarCariprazine Hcl37$52,322
XareltoRivaroxaban25$29,523
JanuviaSitagliptin Phosphate42$26,500
LinzessLinaclotide43$26,149
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen772$22,264
MyrbetriqMirabegron30$14,930
JardianceEmpagliflozin14$14,296
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,998
EntrestoSacubitril/Valsartan17$12,344
Combivent RespimatIpratropium/Albuterol Sulfate25$12,049
SymbicortBudesonide/Formoterol Fumarate53$11,623
BrilintaTicagrelor17$10,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$230$134,737128 claims
AbbVieVraylar, Linzess$414$78,47180 claims
PfizerEliquis$15$72,267108 claims
Novo NordiskOzempic$125$57,77157 claims
Johnson & JohnsonXarelto, Invokamet$111$36,87337 claims
AstraZenecaSymbicort, Brilinta, Farxiga$110$29,38581 claims
Astellas Pharma US IncMyrbetriq$21$14,93030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Alma

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →